{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:07:51Z","timestamp":1788826071179,"version":"build-2803163510"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T00:00:00Z","timestamp":1744934400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T00:00:00Z","timestamp":1744934400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-06407-4","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T23:36:10Z","timestamp":1744932970000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Malignant mesothelioma-associated inflammatory microenvironment promotes tumor progression via GPNMB"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6986-9594","authenticated-orcid":false,"given":"Cristina","family":"Belgiovine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Digifico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Erreni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Rita","family":"Putignano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Mannarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Valentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Grizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Pasqualini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Recordati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Bertola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Zucali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Pistillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Paleari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Mantovani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"D\u2019Incalci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Marchesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Allavena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,18]]},"reference":[{"key":"6407_CR1","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","volume":"14","author":"A Mantovani","year":"2017","unstructured":"Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumor-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol. 2017;14:399.","journal-title":"Nat Rev Clin Oncol"},{"key":"6407_CR2","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41573-022-00520-5","volume":"21","author":"A Mantovani","year":"2022","unstructured":"Mantovani A, Allavena P, Marchesi F, Garlanda C. Macrophages as tools and targets in cancer therapy. Nat Rev Drug Discov. 2022;21:799\u2013820.","journal-title":"Nat Rev Drug Discov"},{"key":"6407_CR3","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/s41577-019-0127-6","volume":"19","author":"DG DeNardo","year":"2019","unstructured":"DeNardo DG, Ruffell B. Macrophages as regulators of tumor immunity and immunotherapy. Nat Rev Immunol. 2019;19:369.","journal-title":"Nat Rev Immunol"},{"key":"6407_CR4","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41571-022-00620-6","volume":"19","author":"MJ Pittet","year":"2022","unstructured":"Pittet MJ, Michielin O, Migliorini D. Clinical relevance of tumour-associated macrophages. Nat Rev Clin Oncol. 2022;19:402\u201321.","journal-title":"Nat Rev Clin Oncol"},{"key":"6407_CR5","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/j.cell.2023.02.020","volume":"186","author":"DJ Kloosterman","year":"2023","unstructured":"Kloosterman DJ, Akkari L. Macrophages at the interface of the co-evolving cancer ecosystem. Cell. 2023;186:1627\u201351.","journal-title":"Cell"},{"key":"6407_CR6","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/s41568-022-00547-1","volume":"23","author":"L Cassetta","year":"2023","unstructured":"Cassetta L, Pollard JW. A timeline of tumour-associated macrophage biology. Nat Rev Cancer. 2023;23:238\u201357.","journal-title":"Nat Rev Cancer"},{"key":"6407_CR7","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.ccell.2024.04.002","volume":"42","author":"C Bl\u00e9riot","year":"2024","unstructured":"Bl\u00e9riot C, Dunsmore G, Alonso-Curbelo D, Ginhoux F. A temporal perspective for tumor-associated macrophage identities and functions. Cancer Cell. 2024;42:747\u201358.","journal-title":"Cancer Cell"},{"issue":"185","key":"6407_CR8","first-page":"642","volume":"1950","author":"G Solinas","year":"2010","unstructured":"Solinas G, et al. Tumor-conditioned macrophages secrete migration-stimulating factor: a new marker for M2-polarization, influencing tumor cell motility. J Immunol Baltim Md. 2010;1950(185):642\u201352.","journal-title":"J Immunol Baltim Md"},{"key":"6407_CR9","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/s41423-020-0501-0","volume":"18","author":"M Liguori","year":"2021","unstructured":"Liguori M, et al. The soluble glycoprotein NMB (GPNMB) produced by macrophages induces cancer stemness and metastasis via CD44 and IL-33. Cell Mol Immunol. 2021;18:711\u201322.","journal-title":"Cell Mol Immunol"},{"key":"6407_CR10","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1158\/1078-0432.CCR-18-0330","volume":"25","author":"M Kobayashi","year":"2019","unstructured":"Kobayashi M, et al. Blocking monocytic myeloid-derived suppressor cell function via anti-DC-HIL\/GPNMB antibody restores the in vitro integrity of T cells from cancer patients. Clin Cancer Res Off J Am Assoc Cancer Res. 2019;25:828\u201338.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res."},{"key":"6407_CR11","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/ijc.2910600111","volume":"60","author":"MA Weterman","year":"1995","unstructured":"Weterman MA, et al. nmb, a novel gene, is expressed in low-metastatic human melanoma cell lines and xenografts. Int J Cancer. 1995;60:73\u201381.","journal-title":"Int J Cancer"},{"key":"6407_CR12","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/jcb.1259","volume":"84","author":"FF Safadi","year":"2001","unstructured":"Safadi FF, et al. Cloning and characterization of osteoactivin, a novel cDNA expressed in osteoblasts. J Cell Biochem. 2001;84:12\u201326.","journal-title":"J Cell Biochem"},{"key":"6407_CR13","doi-asserted-by":"publisher","first-page":"8125","DOI":"10.1074\/jbc.M008539200","volume":"276","author":"S Shikano","year":"2001","unstructured":"Shikano S, Bonkobara M, Zukas PK, Ariizumi K. Molecular cloning of a dendritic cell-associated transmembrane protein, DC-HIL, that promotes RGD-dependent adhesion of endothelial cells through recognition of heparan sulfate proteoglycans. J Biol Chem. 2001;276:8125\u201334.","journal-title":"J Biol Chem"},{"key":"6407_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0012093","volume":"5","author":"AAN Rose","year":"2010","unstructured":"Rose AAN, et al. ADAM10 releases a soluble form of the GPNMB\/Osteoactivin extracellular domain with angiogenic properties. PLoS ONE. 2010;5: e12093.","journal-title":"PLoS ONE"},{"key":"6407_CR15","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1002\/jcb.25394","volume":"117","author":"B Yu","year":"2016","unstructured":"Yu B, Sondag GR, Malcuit C, Kim M-H, Safadi FF. Macrophage-associated osteoactivin\/GPNMB mediates mesenchymal stem cell survival, proliferation, and migration via a CD44-dependent mechanism. J Cell Biochem. 2016;117:1511\u201321.","journal-title":"J Cell Biochem"},{"key":"6407_CR16","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1016\/j.yexcr.2008.02.006","volume":"314","author":"SM Abdelmagid","year":"2008","unstructured":"Abdelmagid SM, et al. Osteoactivin, an anabolic factor that regulates osteoblast differentiation and function. Exp Cell Res. 2008;314:2334\u201351.","journal-title":"Exp Cell Res"},{"key":"6407_CR17","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.jid.2017.08.034","volume":"138","author":"B Yu","year":"2018","unstructured":"Yu B, Alboslemy T, Safadi F, Kim M-H. Glycoprotein nonmelanoma clone B regulates the crosstalk between macrophages and mesenchymal stem cells toward wound repair. J Invest Dermatol. 2018;138:219\u201327.","journal-title":"J Invest Dermatol"},{"key":"6407_CR18","doi-asserted-by":"publisher","first-page":"19614","DOI":"10.1038\/s41598-021-99090-6","volume":"11","author":"B Nickl","year":"2021","unstructured":"Nickl B, Qadri F, Bader M. Anti-inflammatory role of Gpnmb in adipose tissue of mice. Sci Rep. 2021;11:19614.","journal-title":"Sci Rep"},{"key":"6407_CR19","doi-asserted-by":"publisher","first-page":"6522","DOI":"10.1038\/s41598-022-10522-3","volume":"12","author":"M Suda","year":"2022","unstructured":"Suda M, et al. Glycoprotein nonmetastatic melanoma protein B regulates lysosomal integrity and lifespan of senescent cells. Sci Rep. 2022;12:6522.","journal-title":"Sci Rep"},{"key":"6407_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2024.150386","volume":"732","author":"X Yu","year":"2024","unstructured":"Yu X, Li M, Wang C, Guan X. Glycoprotein non-metastatic melanoma protein B (GPNMB): an attractive target in atherosclerosis. Biochem Biophys Res Commun. 2024;732: 150386.","journal-title":"Biochem Biophys Res Commun"},{"issue":"178","key":"6407_CR21","first-page":"6557","volume":"1950","author":"VM Ripoll","year":"2007","unstructured":"Ripoll VM, Irvine KM, Ravasi T, Sweet MJ, Hume DA. Gpnmb is induced in macrophages by IFN-gamma and lipopolysaccharide and acts as a feedback regulator of proinflammatory responses. J Immunol Baltim Md. 2007;1950(178):6557\u201366.","journal-title":"J Immunol Baltim Md"},{"key":"6407_CR22","first-page":"4767","volume":"24","author":"B Li","year":"2010","unstructured":"Li B, et al. The melanoma-associated transmembrane glycoprotein Gpnmb controls trafficking of cellular debris for degradation and is essential for tissue repair. FASEB J Off Publ Fed Am Soc Exp Biol. 2010;24:4767\u201381.","journal-title":"FASEB J Off Publ Fed Am Soc Exp Biol."},{"key":"6407_CR23","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1158\/1078-0432.CCR-19-2360","volume":"26","author":"J-S Chung","year":"2020","unstructured":"Chung J-S, et al. DC-HIL\/Gpnmb is a negative regulator of tumor response to immune checkpoint inhibitors. Clin Cancer Res Off J Am Assoc Cancer Res. 2020;26:1449\u201359.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res."},{"key":"6407_CR24","doi-asserted-by":"publisher","first-page":"4573","DOI":"10.1038\/s41388-022-02443-2","volume":"41","author":"A-M Lazaratos","year":"2022","unstructured":"Lazaratos A-M, Annis MG, Siegel PM. GPNMB: a potent inducer of immunosuppression in cancer. Oncogene. 2022;41:4573\u201390.","journal-title":"Oncogene"},{"key":"6407_CR25","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1016\/j.jid.2021.10.004","volume":"142","author":"V Ramani","year":"2022","unstructured":"Ramani V, Chung J-S, Ariizumi K, Cruz PD. Soluble DC-HIL\/Gpnmb modulates T-lymphocyte extravasation to inflamed skin. J Invest Dermatol. 2022;142:1372-1380.e5.","journal-title":"J Invest Dermatol"},{"key":"6407_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.674739","author":"M Saade","year":"2021","unstructured":"Saade M, AraujodeSouza G, Scavone C, Kinoshita PF. The role of GPNMB in inflammation. Front Immunol. 2021. https:\/\/doi.org\/10.3389\/fimmu.2021.674739.","journal-title":"Front Immunol"},{"key":"6407_CR27","doi-asserted-by":"publisher","first-page":"7503","DOI":"10.3892\/mmr.2015.4408","volume":"12","author":"F Sasaki","year":"2015","unstructured":"Sasaki F, et al. Expression of glycoprotein nonmetastatic melanoma protein B in macrophages infiltrating injured mucosa is associated with the severity of experimental colitis in mice. Mol Med Rep. 2015;12:7503\u201311.","journal-title":"Mol Med Rep"},{"key":"6407_CR28","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1038\/ki.2011.28","volume":"79","author":"M Patel-Chamberlin","year":"2011","unstructured":"Patel-Chamberlin M, et al. Hematopoietic growth factor inducible neurokinin-1 (Gpnmb\/Osteoactivin) is a biomarker of progressive renal injury across species. Kidney Int. 2011;79:1138\u201348.","journal-title":"Kidney Int"},{"key":"6407_CR29","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.cellimm.2017.03.006","volume":"316","author":"L Zhou","year":"2017","unstructured":"Zhou L, et al. Glycoprotein non-metastatic melanoma protein b (Gpnmb) is highly expressed in macrophages of acute injured kidney and promotes M2 macrophages polarization. Cell Immunol. 2017;316:53\u201360.","journal-title":"Cell Immunol"},{"key":"6407_CR30","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s40478-018-0612-3","volume":"6","author":"M H\u00fcttenrauch","year":"2018","unstructured":"H\u00fcttenrauch M, et al. Glycoprotein NMB: a novel Alzheimer\u2019s disease associated marker expressed in a subset of activated microglia. Acta Neuropathol Commun. 2018;6:108.","journal-title":"Acta Neuropathol Commun"},{"key":"6407_CR31","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s10048-017-0514-8","volume":"18","author":"MN Murthy","year":"2017","unstructured":"Murthy MN, et al. Increased brain expression of GPNMB is associated with genome wide significant risk for Parkinson\u2019s disease on chromosome 7p15.3. Neurogenetics. 2017;18:121\u201333.","journal-title":"Neurogenetics"},{"key":"6407_CR32","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.neuroscience.2014.06.065","volume":"277","author":"Y Nakano","year":"2014","unstructured":"Nakano Y, et al. Glycoprotein nonmetastatic melanoma protein B (GPNMB) as a novel neuroprotective factor in cerebral ischemia-reperfusion injury. Neuroscience. 2014;277:123\u201331.","journal-title":"Neuroscience"},{"key":"6407_CR33","doi-asserted-by":"publisher","first-page":"23241","DOI":"10.1038\/srep23241","volume":"6","author":"Y Ono","year":"2016","unstructured":"Ono Y, Tsuruma K, Takata M, Shimazawa M, Hara H. Glycoprotein nonmetastatic melanoma protein B extracellular fragment shows neuroprotective effects and activates the PI3K\/Akt and MEK\/ERK pathways via the Na+\/K+-ATPase. Sci Rep. 2016;6:23241.","journal-title":"Sci Rep"},{"key":"6407_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2021.101232","volume":"297","author":"A Prabata","year":"2021","unstructured":"Prabata A, Ikeda K, Rahardini EP, Hirata K-I, Emoto N. GPNMB plays a protective role against obesity-related metabolic disorders by reducing macrophage inflammatory capacity. J Biol Chem. 2021;297: 101232.","journal-title":"J Biol Chem"},{"key":"6407_CR35","first-page":"639","volume":"131","author":"V Bianco","year":"2023","unstructured":"Bianco V, Kratky D. Glycoprotein non-metastatic protein B (GPNMB): the missing link between lysosomes and obesity. Exp Clin Endocrinol Diabetes Off J Ger Soc Endocrinol Ger Diabetes Assoc. 2023;131:639\u201345.","journal-title":"Exp Clin Endocrinol Diabetes Off J Ger Soc Endocrinol Ger Diabetes Assoc."},{"key":"6407_CR36","first-page":"8810","volume":"34","author":"P-S Tsou","year":"2020","unstructured":"Tsou P-S, Sawalha AH. Glycoprotein nonmetastatic melanoma protein B: a key mediator and an emerging therapeutic target in autoimmune diseases. FASEB J Off Publ Fed Am Soc Exp Biol. 2020;34:8810\u201323.","journal-title":"FASEB J Off Publ Fed Am Soc Exp Biol."},{"key":"6407_CR37","first-page":"839","volume":"6","author":"G Maric","year":"2013","unstructured":"Maric G, Rose AA, Annis MG, Siegel PM. Glycoprotein non-metastatic b (GPNMB): a metastatic mediator and emerging therapeutic target in cancer. OncoTargets Ther. 2013;6:839\u201352.","journal-title":"OncoTargets Ther"},{"key":"6407_CR38","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1158\/1078-0432.CCR-05-2797","volume":"12","author":"C-T Kuan","year":"2006","unstructured":"Kuan C-T, et al. Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme. Clin Cancer Res Off J Am Assoc Cancer Res. 2006;12:1970\u201382.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res."},{"key":"6407_CR39","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.steroids.2017.10.013","volume":"133","author":"M Taya","year":"2018","unstructured":"Taya M, Hammes SR. Glycoprotein non-metastatic melanoma protein B (GPNMB) and cancer: a novel potential therapeutic target. Steroids. 2018;133:102\u20137.","journal-title":"Steroids"},{"key":"6407_CR40","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.7150\/jca.92661","volume":"15","author":"Q Liu","year":"2024","unstructured":"Liu Q, et al. GPNMB expression associates with inferior prognosis in patients with small cell lung cancer. J Cancer. 2024;15:2960\u201370.","journal-title":"J Cancer"},{"key":"6407_CR41","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1158\/1078-0432.CCR-09-1611","volume":"16","author":"AAN Rose","year":"2010","unstructured":"Rose AAN, et al. Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2010;16:2147\u201356.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res."},{"key":"6407_CR42","doi-asserted-by":"publisher","first-page":"5778","DOI":"10.1158\/0008-5472.CAN-09-2538","volume":"70","author":"M Tomihari","year":"2010","unstructured":"Tomihari M, Chung J-S, Akiyoshi H, Cruz PD, Ariizumi K. DC-HIL\/glycoprotein Nmb promotes growth of melanoma in mice by inhibiting the activation of tumor-reactive T cells. Cancer Res. 2010;70:5778\u201387.","journal-title":"Cancer Res"},{"key":"6407_CR43","doi-asserted-by":"publisher","first-page":"5294","DOI":"10.1038\/s41388-019-0793-7","volume":"38","author":"G Maric","year":"2019","unstructured":"Maric G, et al. GPNMB augments Wnt-1 mediated breast tumor initiation and growth by enhancing PI3K\/AKT\/mTOR pathway signaling and \u03b2-catenin activity. Oncogene. 2019;38:5294\u2013307.","journal-title":"Oncogene"},{"key":"6407_CR44","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1177\/1535370216654224","volume":"241","author":"G Bao","year":"2016","unstructured":"Bao G, et al. Glycoprotein non-metastaticmelanoma protein B promotes glioma motility and angiogenesis through the Wnt\/\u03b2-catenin signaling pathway. Exp Biol Med. 2016;241:1968\u201376.","journal-title":"Exp Biol Med"},{"key":"6407_CR45","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.bbrc.2016.11.034","volume":"481","author":"Y Ono","year":"2016","unstructured":"Ono Y, et al. Glycoprotein nonmetastatic melanoma protein B (GPNMB) promotes the progression of brain glioblastoma via Na+\/K+-ATPase. Biochem Biophys Res Commun. 2016;481:7\u201312.","journal-title":"Biochem Biophys Res Commun"},{"key":"6407_CR46","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s40478-024-01754-7","volume":"12","author":"F Yalcin","year":"2024","unstructured":"Yalcin F, et al. Tumor associated microglia\/macrophages utilize GPNMB to promote tumor growth and alter immune cell infiltration in glioma. Acta Neuropathol Commun. 2024;12:50.","journal-title":"Acta Neuropathol Commun"},{"key":"6407_CR47","doi-asserted-by":"publisher","first-page":"4187","DOI":"10.1111\/cas.15090","volume":"112","author":"C Wang","year":"2021","unstructured":"Wang C, et al. Glycoprotein non-metastatic melanoma protein B functions with growth factor signaling to induce tumorigenesis through its serine phosphorylation. Cancer Sci. 2021;112:4187\u201397.","journal-title":"Cancer Sci"},{"key":"6407_CR48","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1002\/jcp.25900","volume":"233","author":"OA Arosarena","year":"2018","unstructured":"Arosarena OA, et al. Osteoactivin regulates head and neck squamous cell carcinoma invasion by modulating matrix metalloproteases. J Cell Physiol. 2018;233:409\u201321.","journal-title":"J Cell Physiol"},{"key":"6407_CR49","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1002\/jcb.24621","volume":"114","author":"X Hu","year":"2013","unstructured":"Hu X, Zhang P, Xu Z, Chen H, Xie X. GPNMB enhances bone regeneration by promoting angiogenesis and osteogenesis: potential role for tissue engineering bone. J Cell Biochem. 2013;114:2729\u201337.","journal-title":"J Cell Biochem"},{"key":"6407_CR50","doi-asserted-by":"publisher","first-page":"6424","DOI":"10.1158\/0008-5472.CAN-18-0599","volume":"78","author":"C Chen","year":"2018","unstructured":"Chen C, et al. Glycoprotein nmb is exposed on the surface of dormant breast cancer cells and induces stem cell-like properties. Cancer Res. 2018;78:6424\u201335.","journal-title":"Cancer Res"},{"key":"6407_CR51","doi-asserted-by":"publisher","first-page":"1610450","DOI":"10.3389\/pore.2022.1610450","volume":"28","author":"Y Kawasaki","year":"2022","unstructured":"Kawasaki Y, et al. GPNMB-positive cells in head and neck squamous cell carcinoma-their roles in cancer stemness, therapy resistance, and metastasis. Pathol Oncol Res POR. 2022;28:1610450.","journal-title":"Pathol Oncol Res POR"},{"key":"6407_CR52","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6887","volume":"13","author":"B Wang","year":"2024","unstructured":"Wang B, Wang L, Shang R, Xie L. MDSC suppresses T cell antitumor immunity in CAC via GPNMB in a MyD88-dependent manner. Cancer Med. 2024;13: e6887.","journal-title":"Cancer Med"},{"key":"6407_CR53","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2023114060","volume":"42","author":"Y Meng","year":"2023","unstructured":"Meng Y, et al. GPNMB+Gal-3+ hepatic parenchymal cells promote immunosuppression and hepatocellular carcinogenesis. EMBO J. 2023;42: e114060.","journal-title":"EMBO J"},{"key":"6407_CR54","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aak9397","volume":"10","author":"Y Okita","year":"2017","unstructured":"Okita Y, et al. The transcription factor MAFK induces EMT and malignant progression of triple-negative breast cancer cells through its target GPNMB. Sci Signal. 2017;10: eaak9397.","journal-title":"Sci Signal."},{"key":"6407_CR55","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.3892\/ol.2020.11787","volume":"20","author":"X Feng","year":"2020","unstructured":"Feng X, et al. High expression of GPNMB indicates an unfavorable prognosis in glioma: combination of data from the GEO and CGGA databases and validation in tissue microarray. Oncol Lett. 2020;20:2356\u201368.","journal-title":"Oncol Lett"},{"key":"6407_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-023-05608-3","volume":"14","author":"S Son","year":"2023","unstructured":"Son S, et al. CCN3\/NOV promotes metastasis and tumor progression via GPNMB-induced EGFR activation in triple-negative breast cancer. Cell Death Dis. 2023;14:1\u201316.","journal-title":"Cell Death Dis"},{"key":"6407_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.108199","volume":"101","author":"X Xu","year":"2021","unstructured":"Xu X, et al. Adaptive resistance in tumors to anti-PD-1 therapy through re-immunosuppression by upregulation of GPNMB expression. Int Immunopharmacol. 2021;101: 108199.","journal-title":"Int Immunopharmacol"},{"key":"6407_CR58","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1111\/pin.13419","volume":"74","author":"T Kimura","year":"2024","unstructured":"Kimura T, et al. Glycoprotein nonmetastatic melanoma protein B impacts the malignant potential of bladder cancer cells through its hem-immunoreceptor tyrosine-based activation motif. Pathol Int. 2024;74:262\u201373.","journal-title":"Pathol Int"},{"key":"6407_CR59","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.cell.2019.10.003","volume":"179","author":"Q Zhang","year":"2019","unstructured":"Zhang Q, et al. Landscape and dynamics of single immune cells in hepatocellular carcinoma. Cell. 2019;179:829-845.e20.","journal-title":"Cell"},{"key":"6407_CR60","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s12967-019-1908-1","volume":"17","author":"X Sun","year":"2019","unstructured":"Sun X, Liu X, Xia M, Shao Y, Zhang XD. Multicellular gene network analysis identifies a macrophage-related gene signature predictive of therapeutic response and prognosis of gliomas. J Transl Med. 2019;17:159.","journal-title":"J Transl Med"},{"key":"6407_CR61","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1158\/2326-6066.CIR-22-0462","volume":"11","author":"N Cortese","year":"2023","unstructured":"Cortese N, et al. High-resolution analysis of mononuclear phagocytes reveals GPNMB as a prognostic marker in human colorectal liver metastasis. Cancer Immunol Res. 2023;11:405\u201320.","journal-title":"Cancer Immunol Res"},{"key":"6407_CR62","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/nrc.2017.42","volume":"17","author":"TA Yap","year":"2017","unstructured":"Yap TA, Aerts JG, Popat S, Fennell DA. Novel insights into mesothelioma biology and implications for therapy. Nat Rev Cancer. 2017;17:475\u201388.","journal-title":"Nat Rev Cancer"},{"key":"6407_CR63","doi-asserted-by":"publisher","first-page":"402","DOI":"10.3322\/caac.21572","volume":"69","author":"M Carbone","year":"2019","unstructured":"Carbone M, et al. Mesothelioma: scientific clues for prevention, diagnosis, and therapy. CA Cancer J Clin. 2019;69:402\u201329.","journal-title":"CA Cancer J Clin"},{"key":"6407_CR64","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/s41571-022-00649-7","volume":"19","author":"DA Fennell","year":"2022","unstructured":"Fennell DA, Dulloo S, Harber J. Immunotherapy approaches for malignant pleural mesothelioma. Nat Rev Clin Oncol. 2022;19:573\u201384.","journal-title":"Nat Rev Clin Oncol"},{"key":"6407_CR65","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/ng.3520","volume":"48","author":"R Bueno","year":"2016","unstructured":"Bueno R, et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet. 2016;48:407\u201316.","journal-title":"Nat Genet"},{"key":"6407_CR66","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1080\/14656566.2022.2072211","volume":"23","author":"PA Zucali","year":"2022","unstructured":"Zucali PA, et al. Advances in drug treatments for mesothelioma. Expert Opin Pharmacother. 2022;23:929\u201346.","journal-title":"Expert Opin Pharmacother"},{"key":"6407_CR67","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1200\/JCO.21.01567","volume":"40","author":"AS Tsao","year":"2022","unstructured":"Tsao AS, Pass HI, Rimner A, Mansfield AS. New era for malignant pleural mesothelioma: updates on therapeutic options. J Clin Oncol Off J Am Soc Clin Oncol. 2022;40:681\u201392.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"6407_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104481","volume":"203","author":"M Occhipinti","year":"2024","unstructured":"Occhipinti M, et al. Unleashing precision: a review of targeted approaches in pleural mesothelioma. Crit Rev Oncol Hematol. 2024;203: 104481.","journal-title":"Crit Rev Oncol Hematol"},{"key":"6407_CR69","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv1507","volume":"44","author":"A Colaprico","year":"2016","unstructured":"Colaprico A, et al. TCGAbiolinks: an R\/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res. 2016;44: e71.","journal-title":"Nucleic Acids Res"},{"key":"6407_CR70","unstructured":"Team RC. A language and environment for statistical computing. In: R foundation for statistical computing. 2021."},{"key":"6407_CR71","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.","journal-title":"Genome Biol"},{"key":"6407_CR72","unstructured":"Therneau, TM. A package for survival analysis in R. 2024."},{"key":"6407_CR73","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/ijc.30412","volume":"140","author":"R V\u00e1zquez","year":"2017","unstructured":"V\u00e1zquez R, et al. Promising in vivo efficacy of the BET bromodomain inhibitor OTX015\/MK-8628 in malignant pleural mesothelioma xenografts. Int J Cancer. 2017;140:197\u2013207.","journal-title":"Int J Cancer"},{"key":"6407_CR74","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1002\/ijc.2910520609","volume":"52","author":"MR Davis","year":"1992","unstructured":"Davis MR, Manning LS, Whitaker D, Garlepp MJ, Robinson BWS. Establishment of a murine model of malignant mesothelioma. Int J Cancer. 1992;52:881\u20136.","journal-title":"Int J Cancer"},{"key":"6407_CR75","doi-asserted-by":"publisher","first-page":"22850","DOI":"10.1038\/srep22850","volume":"6","author":"R Mezzapelle","year":"2016","unstructured":"Mezzapelle R, et al. Human malignant mesothelioma is recapitulated in immunocompetent BALB\/c mice injected with murine AB cells. Sci Rep. 2016;6:22850.","journal-title":"Sci Rep"},{"key":"6407_CR76","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.3390\/cancers12082136","volume":"12","author":"E Digifico","year":"2020","unstructured":"Digifico E, et al. Optimization of a luciferase-expressing non-invasive intrapleural model of malignant mesothelioma in immunocompetent mice. Cancers. 2020;12:2136.","journal-title":"Cancers"},{"key":"6407_CR77","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/ng794","volume":"30","author":"MG Anderson","year":"2002","unstructured":"Anderson MG, et al. Mutations in genes encoding melanosomal proteins cause pigmentary glaucoma in DBA\/2J mice. Nat Genet. 2002;30:81\u20135.","journal-title":"Nat Genet"},{"key":"6407_CR78","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1471-2156-8-45","volume":"8","author":"GR Howell","year":"2007","unstructured":"Howell GR, et al. Absence of glaucoma in DBA\/2J mice homozygous for wild-type versions of Gpnmb and Tyrp1. BMC Genet. 2007;8:45.","journal-title":"BMC Genet"},{"key":"6407_CR79","doi-asserted-by":"publisher","first-page":"1116430","DOI":"10.3389\/fimmu.2023.1116430","volume":"14","author":"E Digifico","year":"2023","unstructured":"Digifico E, et al. Important functional role of the protein osteopontin in the progression of malignant pleural mesothelioma. Front Immunol. 2023;14:1116430.","journal-title":"Front Immunol"},{"key":"6407_CR80","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1261241","volume":"6","author":"E Marcq","year":"2017","unstructured":"Marcq E, et al. Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma. Oncoimmunology. 2017;6: e1261241.","journal-title":"Oncoimmunology"},{"key":"6407_CR81","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000182","volume":"8","author":"T Blondy","year":"2020","unstructured":"Blondy T, et al. Involvement of the M-CSF\/IL-34\/CSF-1R pathway in malignant pleural mesothelioma. J Immunother Cancer. 2020;8: e000182.","journal-title":"J Immunother Cancer"},{"key":"6407_CR82","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1093\/annonc\/mdy086","volume":"29","author":"G Pasello","year":"2018","unstructured":"Pasello G, et al. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time. Ann Oncol Off J Eur Soc Med Oncol. 2018;29:1258\u201365.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"6407_CR83","doi-asserted-by":"publisher","first-page":"2377830","DOI":"10.1080\/2162402X.2024.2377830","volume":"13","author":"C Chatelain","year":"2024","unstructured":"Chatelain C, et al. Interplay between oncolytic measles virus, macrophages and cancer cells induces a proinflammatory tumor microenvironment. Oncoimmunology. 2024;13:2377830.","journal-title":"Oncoimmunology"},{"key":"6407_CR84","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3390\/mps6020035","volume":"6","author":"D Shek","year":"2023","unstructured":"Shek D, et al. Identification and characterisation of infiltrating immune cells in malignant pleural mesothelioma using spatial transcriptomics. Methods Protoc. 2023;6:35.","journal-title":"Methods Protoc"},{"key":"6407_CR85","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.3390\/cells12162048","volume":"12","author":"I Fiorilla","year":"2023","unstructured":"Fiorilla I, et al. Chronic inflammation, oxidative stress and metabolic plasticity: three players driving the pro-tumorigenic microenvironment in malignant mesothelioma. Cells. 2023;12:2048.","journal-title":"Cells"},{"key":"6407_CR86","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104239","volume":"83","author":"A Xiong","year":"2022","unstructured":"Xiong A, Zhang J, Chen Y, Zhang Y, Yang F. Integrated single-cell transcriptomic analyses reveal that GPNMB-high macrophages promote PN-MES transition and impede T cell activation in GBM. EBioMedicine. 2022;83: 104239.","journal-title":"EBioMedicine"},{"key":"6407_CR87","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2210836120","volume":"120","author":"L Wu","year":"2023","unstructured":"Wu L, et al. Defining and targeting tumor-associated macrophages in malignant mesothelioma. Proc Natl Acad Sci USA. 2023;120: e2210836120.","journal-title":"Proc Natl Acad Sci USA"},{"key":"6407_CR88","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12967-024-05999-7","volume":"23","author":"Z Fang","year":"2025","unstructured":"Fang Z, et al. Single-cell transcriptomic analysis reveals characteristic feature of macrophage reprogramming in liver Mallory-Denk bodies pathogenesis. J Transl Med. 2025;23:77.","journal-title":"J Transl Med"},{"key":"6407_CR89","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.pharmthera.2017.05.010","volume":"179","author":"AAN Rose","year":"2017","unstructured":"Rose AAN, Biondini M, Curiel R, Siegel PM. Targeting GPNMB with glembatumumab vedotin: current developments and future opportunities for the treatment of cancer. Pharmacol Ther. 2017;179:127\u201341.","journal-title":"Pharmacol Ther"},{"key":"6407_CR90","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41523-021-00244-6","volume":"7","author":"LT Vahdat","year":"2021","unstructured":"Vahdat LT, et al. Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (\u201cMETRIC\u201d): a randomized multicenter study. Npj Breast Cancer. 2021;7:1\u201310.","journal-title":"Npj Breast Cancer"},{"key":"6407_CR91","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1200\/JCO.2014.56.2959","volume":"33","author":"DA Yardley","year":"2015","unstructured":"Yardley DA, et al. EMERGE: a randomized phase II study of the antibody-drug conjugate glembatumumab vedotin in advanced glycoprotein NMB-expressing breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33:1609\u201319.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"121","key":"6407_CR92","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ejca.2019.08.015","volume":"1990","author":"LM Kopp","year":"2019","unstructured":"Kopp LM, et al. Phase II trial of the glycoprotein non-metastatic B-targeted antibody-drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: a report from the Children\u2019s Oncology Group. Eur J Cancer Oxf Engl. 2019;1990(121):177\u201383.","journal-title":"Eur J Cancer Oxf Engl"},{"key":"6407_CR93","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1002\/cncr.31892","volume":"125","author":"PA Ott","year":"2019","unstructured":"Ott PA, et al. A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma. Cancer. 2019;125:1113\u201323.","journal-title":"Cancer"},{"key":"6407_CR94","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1038\/s41388-022-02206-z","volume":"41","author":"M Biondini","year":"2022","unstructured":"Biondini M, et al. HSP90 inhibitors induce GPNMB cell-surface expression by modulating lysosomal positioning and sensitize breast cancer cells to glembatumumab vedotin. Oncogene. 2022;41:1701\u201317.","journal-title":"Oncogene"},{"key":"6407_CR95","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/or.2024.8806","volume":"52","author":"K Ishikawa","year":"2024","unstructured":"Ishikawa K, et al. Antitumor activities of anti-CD44 monoclonal antibodies in mouse xenograft models of esophageal cancer. Oncol Rep. 2024;52:1\u201310.","journal-title":"Oncol Rep"},{"key":"6407_CR96","doi-asserted-by":"publisher","DOI":"10.1007\/s10585-024-10292-4","author":"L-M Mehner","year":"2024","unstructured":"Mehner L-M, Munoz-Sagredo L, Sonnentag SJ, Treffert SM, Orian-Rousseau V. Targeting CD44 and other pleiotropic co-receptors as a means for broad inhibition of tumor growth and metastasis. Clin Exp Metastasis. 2024. https:\/\/doi.org\/10.1007\/s10585-024-10292-4.","journal-title":"Clin Exp Metastasis"},{"key":"6407_CR97","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12931-017-0546-5","volume":"18","author":"L Cortes-Dericks","year":"2017","unstructured":"Cortes-Dericks L, Schmid RA. CD44 and its ligand hyaluronan as potential biomarkers in malignant pleural mesothelioma: evidence and perspectives. Respir Res. 2017;18:58.","journal-title":"Respir Res"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06407-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-06407-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06407-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T01:01:35Z","timestamp":1744938095000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-025-06407-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,18]]},"references-count":97,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6407"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-06407-4","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,18]]},"assertion":[{"value":"15 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The methods were performed following the approved guidelines, and all experimental protocols were approved by the ethics committee of the IRCCS Humanitas Research Hospital, Rozzano (Milano), Italy.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors contributed to the article and approved the submitted version.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No potential competing interests was associated with this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"454"}}